Acumen Pharmaceuticals Stock Market Outlook
| ABOS Stock | USD 2.39 0.17 6.64% |
Slightly above 54% of Acumen Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Acumen Pharmaceuticals suggests that many traders are impartial. Acumen Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Acumen Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 46
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Acumen Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Acumen Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Acumen Pharmaceuticals is 'Strong Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Acumen Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Acumen Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Acumen Pharmaceuticals Advice
The Acumen recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Acumen Pharmaceuticals. Macroaxis does not own or have any residual interests in Acumen Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Acumen Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Acumen Pharmaceuticals has a Risk Adjusted Performance of 0.0793, Jensen Alpha of 0.5223, Total Risk Alpha of 0.0712, Sortino Ratio of 0.1005 and Treynor Ratio of 5.23We provide trade advice to complement the prevailing expert consensus on Acumen Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Acumen Pharmaceuticals is not overpriced, please confirm all Acumen Pharmaceuticals fundamentals, including its cash flow from operations, and the relationship between the cash and equivalents and number of employees . Please also double-check Acumen Pharmaceuticals price to book to validate your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Acumen Pharmaceuticals Trading Alerts and Improvement Suggestions
| Acumen Pharmaceuticals is way too risky over 90 days horizon | |
| Acumen Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Acumen Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (102.33 M) with loss before overhead, payroll, taxes, and interest of (118.93 M). | |
| Acumen Pharmaceuticals currently holds about 189.91 M in cash with (86.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Acumen Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Assessing Acumen Pharmaceuticals Valuation After New Phase 2 ALTITUDE-AD Trial Developments |
Acumen Pharmaceuticals current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acumen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acumen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Acumen Pharmaceuticals Returns Distribution Density
The distribution of Acumen Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Acumen Pharmaceuticals' future price movements. The chart of the probability distribution of Acumen Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Acumen Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Acumen Pharmaceuticals returns is essential to provide solid investment analysis for Acumen Pharmaceuticals.
| Mean Return | 0.54 | Value At Risk | -7.18 | Potential Upside | 9.94 | Standard Deviation | 6.15 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Acumen Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Acumen Stock Institutional Investors
The Acumen Pharmaceuticals' institutional investors refer to entities that pool money to purchase Acumen Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Hudson Bay Capital Management Lp | 2025-06-30 | 825 K | Two Sigma Advisers, Llc | 2025-06-30 | 426.3 K | Geode Capital Management, Llc | 2025-06-30 | 396.6 K | Goldman Sachs Group Inc | 2025-06-30 | 334.7 K | Blackrock Inc | 2025-06-30 | 292 K | Ikarian Capital, Llc | 2025-06-30 | 265.8 K | Y-intercept (hong Kong) Ltd | 2025-06-30 | 250.8 K | Renaissance Technologies Corp | 2025-06-30 | 246.6 K | Two Sigma Investments Llc | 2025-06-30 | 200.8 K | Ra Capital Management, Llc | 2025-06-30 | 14.9 M | Sands Capital Ventures, Llc | 2025-06-30 | 3.4 M |
Acumen Pharmaceuticals Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 78.4M | 7.9M | (63.0M) | (31.3M) | (28.1M) | (26.7M) | |
| Free Cash Flow | (18.0M) | (35.3M) | (43.1M) | (86.2M) | (77.6M) | (73.7M) | |
| Other Non Cash Items | 81.4M | 487K | (888K) | (5.4M) | (4.8M) | (4.6M) | |
| Net Income | (100.6M) | (42.9M) | (52.4M) | (102.3M) | (92.1M) | (87.5M) | |
| End Period Cash Flow | 122.2M | 130.1M | 67.1M | 35.9M | 41.2M | 74.4M |
Acumen Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Acumen Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Acumen Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Acumen stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.52 | |
β | Beta against Dow Jones | 0.10 | |
σ | Overall volatility | 6.15 | |
Ir | Information ratio | 0.08 |
Acumen Pharmaceuticals Volatility Alert
Acumen Pharmaceuticals is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Acumen Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Acumen Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Acumen Pharmaceuticals Fundamentals Vs Peers
Comparing Acumen Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Acumen Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Acumen Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Acumen Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Acumen Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Acumen Pharmaceuticals to competition |
| Fundamentals | Acumen Pharmaceuticals | Peer Average |
| Return On Equity | -0.86 | -0.31 |
| Return On Asset | -0.42 | -0.14 |
| Current Valuation | 49.3 M | 16.62 B |
| Shares Outstanding | 60.57 M | 571.82 M |
| Shares Owned By Insiders | 7.46 % | 10.09 % |
| Shares Owned By Institutions | 64.45 % | 39.21 % |
| Number Of Shares Shorted | 900.17 K | 4.71 M |
| Price To Book | 1.56 X | 9.51 X |
| Price To Sales | 538.78 X | 11.42 X |
| Gross Profit | (118.93 M) | 27.38 B |
| EBITDA | (98.08 M) | 3.9 B |
| Net Income | (102.33 M) | 570.98 M |
| Cash And Equivalents | 189.91 M | 2.7 B |
| Cash Per Share | 4.69 X | 5.01 X |
| Total Debt | 29.7 M | 5.32 B |
| Current Ratio | 37.21 X | 2.16 X |
| Book Value Per Share | 1.54 X | 1.93 K |
| Cash Flow From Operations | (86.22 M) | 971.22 M |
| Short Ratio | 0.76 X | 4.00 X |
| Earnings Per Share | (2.21) X | 3.12 X |
| Price To Earnings To Growth | (0.23) X | 4.89 X |
| Target Price | 7.0 | |
| Number Of Employees | 61 | 18.84 K |
| Beta | 0.25 | -0.15 |
| Market Capitalization | 144.77 M | 19.03 B |
| Total Asset | 238.99 M | 29.47 B |
| Retained Earnings | (325.13 M) | 9.33 B |
| Working Capital | 150.7 M | 1.48 B |
| Net Asset | 238.99 M |
Note: Disposition of 2689 shares by Oconnell Daniel Joseph of Acumen Pharmaceuticals at 1.8838 subject to Rule 16b-3 [view details]
Acumen Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Acumen . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Acumen Pharmaceuticals Target Price Consensus
Acumen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Acumen Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Acumen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Acumen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Acumen Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAcumen Pharmaceuticals Target Price Projection
Acumen Pharmaceuticals' current and average target prices are 2.39 and 7.00, respectively. The current price of Acumen Pharmaceuticals is the price at which Acumen Pharmaceuticals is currently trading. On the other hand, Acumen Pharmaceuticals' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Acumen Pharmaceuticals Market Quote on 14th of February 2026
Target Price
Analyst Consensus On Acumen Pharmaceuticals Target Price
Acumen Pharmaceuticals Analyst Ratings
Acumen Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Acumen Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Acumen Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Acumen Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Acumen Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Acumen Pharmaceuticals? Buying financial instruments such as Acumen Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Acumen Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Services Thematic Idea Now
Communication Services
Companies that provide networking, telecom, and long distance services. The Communication Services theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Services Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.